VEGF共調(diào)節(jié)趨化因子1(VCC1)活性蛋白
Active VEGF Co Regulated Chemokine 1 (VCC1)
CXCL17; SCYB17; DMC; Chemokine C-X-C-Motif Ligand 7; Dendritic cell and monocyte chemokine-like protein
- 編號APC068Hu01
- 物種Homo sapiens (Human,人)相同的名稱,不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點9.3
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 1315¥ 3288¥ 6576¥ 19728¥ 49320
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實驗
VEGF Co-Regulated Chemokine 1 (VCC1), also known as CXC chemokine ligand 17 (CXCL17), is a recently identified secretory protein that functions as both a chemokine and an angiogenic factor. It is primarily expressed in mucosal tissues, particularly in the respiratory and digestive tracts, where it contributes to immune surveillance by recruiting dendritic cells and macrophages. VCC1 demonstrates dual functionality: it promotes angiogenesis through mechanisms synergistic with VEGF while also exerting antimicrobial activities in epithelial barriers. Its expression is often upregulated in inflammatory conditions and various cancers, where it may influence tumor microenvironment formation and immune modulation. Besides,Chemokine C-C-Motif Receptor 8 (CCR8) has been identified as an interactor of VCC1, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human VCC1 and recombinant human CCR8. Briefly, VCC1 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to CCR8-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-VCC1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant human VCC1 and recombinant human CCR8 was shown in Figure 1, the EC50?for this effect is 0.05 μg/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
| APC068Hu01 | VEGF共調(diào)節(jié)趨化因子1(VCC1)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPC068Hu01 | VEGF共調(diào)節(jié)趨化因子1(VCC1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC068Hu01 | VEGF共調(diào)節(jié)趨化因子1(VCC1)多克隆抗體 | WB |
| LAC068Hu71 | VEGF共調(diào)節(jié)趨化因子1(VCC1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAC068Hu22 | VEGF共調(diào)節(jié)趨化因子1(VCC1)單克隆抗體 | WB; IHC; ICC; IP. |
| SEC068Hu | VEGF共調(diào)節(jié)趨化因子1(VCC1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCC068Hu | VEGF共調(diào)節(jié)趨化因子1(VCC1)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMC068Hu | VEGF共調(diào)節(jié)趨化因子1(VCC1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |



